Mirai Bio Explores Nonviral Gene Therapy Safety Amidst Zolgensma Concerns
Rapid Read

Mirai Bio Explores Nonviral Gene Therapy Safety Amidst Zolgensma Concerns

What's Happening? Mirai Bio, a Flagship Pioneering company, is actively developing nonviral gene therapies, particularly using lipid nanoparticles (LNPs), amidst growing safety concerns surrounding viral vectors like adeno-associated viruses (AAVs). Recent reports of spinal cord tumors in nine patie
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.